116 related articles for article (PubMed ID: 31603674)
1. Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
Xu X; Kuang Z; Han J; Meng Y; Li L; Luan H; Xu P; Wang J; Luo C; Ding H; Li Z; Bian J
J Med Chem; 2019 Nov; 62(21):9642-9657. PubMed ID: 31603674
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.
Xu X; Chang X; Huang J; Zhang D; Wang M; Jing T; Zhuang Y; Kou J; Qiu Z; Wang J; Li Z; Bian J
Eur J Med Chem; 2022 Jun; 236():114337. PubMed ID: 35428013
[TBL] [Abstract][Full Text] [Related]
3. Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
Xu X; Wang J; Wang M; Yuan X; Li L; Zhang C; Huang H; Jing T; Wang C; Tong C; Zhou L; Meng Y; Xu P; Kou J; Qiu Z; Li Z; Bian J
J Med Chem; 2021 Apr; 64(8):4588-4611. PubMed ID: 33792311
[TBL] [Abstract][Full Text] [Related]
4. Targeting glutaminase 1 (GLS1) by small molecules for anticancer therapeutics.
Chen Y; Tan L; Gao J; Lin C; Wu F; Li Y; Zhang J
Eur J Med Chem; 2023 Apr; 252():115306. PubMed ID: 36996714
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel Glutaminase allosteric inhibitors through drug repurposing and comparative MMGB/PBSA and molecular dynamics simulation.
Yousaf R; Navid A; Azam SS
Comput Biol Med; 2022 Jul; 146():105669. PubMed ID: 35654625
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.
Jo M; Koizumi K; Suzuki M; Kanayama D; Watanabe Y; Gouda H; Mori H; Mizuguchi M; Obita T; Nabeshima Y; Toyooka N; Okada T
Bioorg Med Chem Lett; 2023 May; 87():129266. PubMed ID: 37011768
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a novel glutaminase inhibitor.
Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS
FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439
[TBL] [Abstract][Full Text] [Related]
8. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group.
Chang X; Wang M; Zhang D; Zhang Y; Wang J; Li Z; Bian J; Xu X
Eur J Med Chem; 2023 Jan; 246():115014. PubMed ID: 36525694
[TBL] [Abstract][Full Text] [Related]
10. Targeting GLS1 to cancer therapy through glutamine metabolism.
Yu W; Yang X; Zhang Q; Sun L; Yuan S; Xin Y
Clin Transl Oncol; 2021 Nov; 23(11):2253-2268. PubMed ID: 34023970
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of Novel Kidney-Type Glutaminase Allosteric Inhibitors Targeting the Critical Lys-320 Residue.
Song J; Pan C; Li J; Bai R; Zeng Z; Han Y; Chen Z; Hou W; Li Y; Ruan BH
ACS Med Chem Lett; 2023 Jan; 14(1):11-17. PubMed ID: 36655131
[TBL] [Abstract][Full Text] [Related]
12. An Economical High-Throughput "FP-Tag" Assay for Screening Glycosyltransferase Inhibitors*.
Yin X; Li J; Chen S; Wu Y; She Z; Liu L; Wang Y; Gao Z
Chembiochem; 2021 Apr; 22(8):1391-1395. PubMed ID: 33259119
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer.
Pan T; Gao L; Wu G; Shen G; Xie S; Wen H; Yang J; Zhou Y; Tu Z; Qian W
Biochem Biophys Res Commun; 2015 Jan; 456(1):452-8. PubMed ID: 25482439
[TBL] [Abstract][Full Text] [Related]
14. Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors.
Lin LC; Chang HY; Lin TE; Lin JR; Hsia SM; Hsu KC; Huang TC
Biomed Pharmacother; 2022 Oct; 154():113585. PubMed ID: 36029536
[TBL] [Abstract][Full Text] [Related]
15. Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
Takahashi S; Saegusa J; Sendo S; Okano T; Akashi K; Irino Y; Morinobu A
Arthritis Res Ther; 2017 Apr; 19(1):76. PubMed ID: 28399896
[TBL] [Abstract][Full Text] [Related]
16. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State.
Daemen A; Liu B; Song K; Kwong M; Gao M; Hong R; Nannini M; Peterson D; Liederer BM; de la Cruz C; Sangaraju D; Jaochico A; Zhao X; Sandoval W; Hunsaker T; Firestein R; Latham S; Sampath D; Evangelista M; Hatzivassiliou G
Cell Metab; 2018 Sep; 28(3):383-399.e9. PubMed ID: 30043751
[TBL] [Abstract][Full Text] [Related]
18. Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization.
Xiang L; Mou J; Shao B; Wei Y; Liang H; Takano N; Semenza GL; Xie G
Cell Death Dis; 2019 Jan; 10(2):40. PubMed ID: 30674873
[TBL] [Abstract][Full Text] [Related]
19. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
Li J; Li X; Wu L; Pei M; Li H; Jiang Y
Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
[TBL] [Abstract][Full Text] [Related]
20. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J
Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
